Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Yu Milovanova

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Terapevticheskii Arkhiv|August 5, 2016
[Difficulties in correcting hyperphosphatemia in patients with chronic renal failure. A place of noncalcium-containing phosphate-binding drugs]Yu S Milovanov, V V Fomin, L Yu Milovanova
Terapevticheskii Arkhiv|April 13, 2016
[The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease]N A Mukhin, Yu S Milovanov, L V Kozlovskaya, et al.
Terapevticheskii Arkhiv|February 1, 2019
HCV-associated mixed cryoglobulinemia and b-cell non-Hodgkin's lymphoma - pathogenetically related problemsS Yu Milovanova, L V Lysenko Kozlovskaya, L Yu Milovanova, et al.
Terapevticheskii Arkhiv|July 27, 2017
[Risk factors for anemia in the early stages of chronic kidney disease]Yu S Milovanov, L V Kozlovskaya, L Yu Milovanova, et al.
Terapevticheskii Arkhiv|February 1, 2019
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltrationL Yu Milovanova, I A Dobrosmyslov, Yu S Milovanov, et al.
Klinicheskaia Meditsina|October 11, 2018
[EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE]N A Mukhin, L Yu Milovanova, V V Fomin, et al.
Terapevticheskii Arkhiv|February 1, 2019
Quality of life of chronic kidney disease patients on renal replacement therapyYu S Milovanov, I A Dobrosmyslov, S Yu Milovanova, et al.
Klinicheskaia Meditsina|May 7, 2016
[MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE]L Yu Milovanova, L V Kozlovskaya, M M Markina, et al.
Terapevticheskii Arkhiv|August 19, 2015
[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease]L Yu Milovanova, Yu S Milovanov, D V Kudryavtseva, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Terapevticheskii Arkhiv|August 5, 2016
[Difficulties in correcting hyperphosphatemia in patients with chronic renal failure. A place of noncalcium-containing phosphate-binding drugs]Yu S Milovanov, V V Fomin, L Yu Milovanova
Terapevticheskii Arkhiv|April 13, 2016
[The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease]N A Mukhin, Yu S Milovanov, L V Kozlovskaya, et al.
Terapevticheskii Arkhiv|February 1, 2019
HCV-associated mixed cryoglobulinemia and b-cell non-Hodgkin's lymphoma - pathogenetically related problemsS Yu Milovanova, L V Lysenko Kozlovskaya, L Yu Milovanova, et al.
Terapevticheskii Arkhiv|July 27, 2017
[Risk factors for anemia in the early stages of chronic kidney disease]Yu S Milovanov, L V Kozlovskaya, L Yu Milovanova, et al.
Terapevticheskii Arkhiv|February 1, 2019
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltrationL Yu Milovanova, I A Dobrosmyslov, Yu S Milovanov, et al.
Klinicheskaia Meditsina|October 11, 2018
[EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE]N A Mukhin, L Yu Milovanova, V V Fomin, et al.
Terapevticheskii Arkhiv|February 1, 2019
Quality of life of chronic kidney disease patients on renal replacement therapyYu S Milovanov, I A Dobrosmyslov, S Yu Milovanova, et al.
Klinicheskaia Meditsina|May 7, 2016
[MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE]L Yu Milovanova, L V Kozlovskaya, M M Markina, et al.
Terapevticheskii Arkhiv|August 19, 2015
[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease]L Yu Milovanova, Yu S Milovanov, D V Kudryavtseva, et al.
Pageof 1